



Universiteit
Leiden
The Netherlands

Novel mechanistic insight in cholesteryl ester transfer protein production and pharmacological inhibition

Tuin, S.J.L. van der

Citation

Tuin, S. J. L. van der. (2017, February 23). *Novel mechanistic insight in cholesteryl ester transfer protein production and pharmacological inhibition*. Retrieved from <https://hdl.handle.net/1887/46114>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/46114>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/46114> holds various files of this Leiden University dissertation

Author: Tuin, Sam van der

Title: Novel mechanistic insight in cholesteryl ester transfer protein production and pharmacological inhibition

Issue Date: 2017-02-23

Novel mechanistic insight in Cholesteryl Ester Transfer Protein production and pharmacological inhibition

1. The principal source of the plasma cholesteryl ester transfer protein (CETP) is the macrophage residing in the liver.
-this thesis-
2. The CETP protein is a prime example of the tight integration of the immune system and lipid metabolism.
-this thesis-
3. Anacetrapib's off-target effects might be more beneficial than its on-target effects.
-this thesis-
4. Although tissue resident macrophages are derived from a common bone marrow derived precursor cell and share a common function, they are characterized by distinct gene expression patterns.
-this thesis-
5. Despite the fact that genetically reduced circulating CETP has been causally associated with a lower cardiovascular disease (CVD) risk, none of the CETP inhibitors have yet shown any clinical benefit.
-Niu et al., Circ. Cardiovasc. Genet. 8 (1), 114-21 (2015)-
6. A single marker for the different stages of NAFLD/NASH is not likely to be found.
-Sanyal et al., Hepatology 61 (4), 1392-1405 (2015)-
7. Reduction of CVD risk by PCSK9 inhibition is partly due to modulating cholesterol homeostasis of macrophages.
-Adorni et al., Atherosclerosis 16 (256), 1-6 (2016)-
8. NAFLD/NASH Fatty liver disease and atherosclerosis are the same disease affecting different organs.
-Bieggs et al., Atherosclerosis 220 (2), 287-293 (2011)-
9. Treatment of cardiovascular disease starts with educating young and healthy children rather than with drugs.
- Mackay et al., The Atlas of Heart Disease and Stroke, World Health Organization (2004)-
10. Soms is 't beater iets moeis te verleeze. Beater verleeze dan dat ge 't nooit het gehad.
-Rowen Héze, Heilige Antonius [Water, Lucht en Liefde (1997)]-